Want to see HK:8049 full AI Analyst Report?

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H (8049) Price & Analysis

2 Followers

8049 Stock Chart & Stats

HK$2.16

-HK$0.03(-2.08%)

At close: Jan 09 4:00 PM EST

HK$2.16

-HK$0.03(-2.08%)

Day’s Range― - ―

52-Week RangeHK$1.82 - HK$3.00

Previous CloseN/A

Volume24.00K

Average Volume (3M)24.27K

Market Cap

HK$1.51B

Enterprise ValueHK$245.91M

Total Cash (Recent Filing)HK$902.41M

Total Debt (Recent Filing)HK$399.93K

Price to Earnings (P/E)4.6

Beta0.31

Next Earnings

Apr 01, 2027

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield11.31%

Share Statistics

EPS (TTM)0.50

Shares Outstanding172,500,000

10 Day Avg. Volume39,200

30 Day Avg. Volume24,266

Financial Highlights & Ratios

PEG Ratio0.92

Price to Book (P/B)0.65

Price to Sales (P/S)1.22

P/FCF Ratio3.65

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Consistent ProfitabilitySustained gross, net, and operating profitability indicates that the company has preserved attractive economics across multiple years. Stable margins provide a durable earnings base, support internal funding for research and commercialization, and make the business less dependent on external capital.

Conservative Balance SheetA low-leverage balance sheet and expanding equity base strengthen financial resilience over the medium term. This capital structure should provide greater capacity to absorb operating volatility, maintain investment in pharmaceutical activities, and pursue opportunities without excessive reliance on borrowing.

Strong Cash GenerationFree cash flow that broadly tracks net income suggests reported profitability is converting into usable cash, rather than remaining largely accounting-based. The strong 2025 improvement increases funding capacity for operations, product development, and shareholder or balance-sheet priorities.

Bears Say

Cooling Revenue MomentumThe recent shift from earlier expansion to flat, modest, and then negative annual revenue growth indicates weaker top-line momentum. If this pattern persists, it could limit operating leverage, reduce the growth contribution to earnings, and make continued profitability more dependent on margin preservation.

Volatile Cash ConversionAlthough recent cash generation is strong, the pronounced year-to-year swings show that cash conversion has not been consistently predictable. Such variability can complicate budgeting and capital allocation, requiring management to preserve liquidity even when reported earnings remain healthy.

Recent Debt IncreaseThe increase in debt during 2023–2024 is a deterioration from the company’s earlier low-debt position, even though leverage remains manageable. Continued borrowing could reduce financial flexibility and increase obligations that compete with investment in the business if the trend extends.

8049 FAQ

What was Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H’s price range in the past 12 months?

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H lowest stock price was HK$1.82 and its highest was HK$3.00 in the past 12 months.

What is Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H’s market cap?

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H’s market cap is HK$1.51B.

When is Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H’s upcoming earnings report date?

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H’s upcoming earnings report date is Apr 01, 2027 which is in 153 days.

How were Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H’s earnings last quarter?

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H released its earnings results on Aug 14, 2026. The company reported HK$0.25 earnings per share for the quarter.

Is Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H overvalued?

According to Wall Street analysts Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H pay dividends?

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H pays a Notavailable dividend of HK$0.287 which represents an annual dividend yield of 11.31%. See more information on Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H dividends here

What is Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H’s EPS estimate?

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H have?

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H has 172,500,000 shares outstanding.

What happened to Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H’s price movement after its last earnings report?

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H reported an EPS of HK$0.25 in its last earnings report. Following the earnings report the stock price went down -3.664%.

Which hedge fund is a major shareholder of Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H?

Currently, no hedge funds are holding shares in HK:8049

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H

Jilin Province Huinan Changlong Bio-pharmacy Company Limited focuses on the manufacturing and sale of traditional Chinese medicines and various pharmaceutical products within the People's Republic of China. The company's extensive product portfolio includes a wide range of dosage forms such as tablets, capsules, and pills, as well as specialized items like Chinese medicine pretreatment and extraction products. They also provide various injectable solutions, including powders for injection, lyophilized powders for injection, and small volume liquid injections, along with active pharmaceutical ingredients (APIs) and granules. These products are primarily sold under the "Changlong" and "Qing Tong" brand names. Established in 1989, and headquartered in Kowloon, Hong Kong, the company was previously known as Jilin Province Huinan Biochemical Pharmaceutical Company Limited.